GE Healthcare and Takeda to take on liver disease R&D together
- GE Healthcare will provide the diagnostic imaging technology to support Takeda's R&D into common liver diseases as part of a newly-formed partnership.
- A primary area of focus will be the two conditions that have, combined, become the number one cause of liver disease in developed countries—non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
- GE's diagnostic imaging technology will be used to generate a liver stiffness map.
Takeda and GE have chosen to take on NAFLD and NASH research in particular because they have almost no visible symptoms, yet lead to liver fibrosis. Epidemiological surveys suggest a median global prevalence rate of 20% for NAFLD. And so far, there has not been a great deal of success in developing anti-fibrotic therapies to treat fibrotic liver diseases.
The consequences of untreated disease can include cirrhosis and portal hypertension, potentially leading to the need for a liver transplant.
- Contract Pharma GE Healthcare, Takeda Enter Liver Disease R&D Alliance